POWAY, Calif., March 19 /PRNewswire-FirstCall/ -- Digirad Corporation , a leading provider of medical diagnostic imaging products and services to physicians’ offices, hospitals and imaging centers, today announced its board of directors has appointed veteran healthcare executive John W. Sayward director and audit committee chairman, effective immediately.
Mr. Sayward, 56, has more than 30 years of finance, accounting, operational and administrative experience in the healthcare industry, and has previously served on the board of a public pharmaceuticals company. He replaces Raymond Dittamore, 65, who resigned from the board and has retired from business. Mr. Dittamore joined the Digirad board in March 2004 and served as chairman of the audit committee.
Digirad Chairman R. King Nelson said, “John Sayward’s extensive operational and financial management background in healthcare and his experience in cardiology will be valuable assets to Digirad as the Company moves forward with its Centers of Excellence expansion strategy and focuses on accelerating its top and bottom line growth.
“We would also like to thank Ray for his many years of providing solid guidance and support of Digirad, and we wish him the very best,” King added.
From September 2005 to January 2007, Mr. Sayward was a partner at Nippon Heart Hospital, LLC (NHH), a healthcare management company, formed to partner with leading cardiologists to improve cardiovascular care and build and manage cardiovascular-care hospitals in Japan. While at NHH, Mr. Sayward helped develop relationships with cardiology leaders, government officials and hospital administrators, managed NHH’s strategic business plan and evaluated alternatives for financing that plan. From 2002 to 2005, he was executive vice president and chief financial officer of LMA North America Inc., a medical device company, where he managed the company’s operations, quality and human resources functions and was a key player in the company’s initial public offering.
Prior to 2002, he was chief financial officer and a director of SICOR, Inc., a $2.5 billion pharmaceuticals company that was acquired by Teva Pharmaceuticals. As a senior executive at SICOR he made significant contributions to a highly successful business turnaround and managed a number of corporate-level transactions including the divestiture of a subsidiary, an acquisition and secured financing for strategic expansion.
Mr. Sayward received his undergraduate degree from Northwestern University and a master of management degree from Kellogg School of Management at Northwestern University.
About Digirad Corporation
Digirad provides diagnostic medical imaging products and services to physicians’ offices, hospitals and imaging centers for cardiac, vascular, and general imaging applications. Digirad’s Cardius XPO line of nuclear imaging cameras use patented solid-state technology and unique multi (single, dual, triple) head design for superior performance and advanced features for sharper digital images, faster processing, compact size, lighter weight for portability, ability to handle patients up to 500 pounds, and improved patient comfort compared to standard nuclear cameras. Digirad’s 2020tc general-purpose nuclear imager has a small footprint and may also be configured for fixed or mobile use to supplement primary imaging. Digirad’s installed base of equipment exceeds 450 systems; in addition, a mobile fleet of more than 120 nuclear and ultrasound imaging systems is being used in 22 states, primarily in the eastern, midwestern and southwestern United States. For more information, please visit http://www.digirad.com. Digirad(R), Digirad Imaging Solutions(R), and Cardius(R) are registered trademarks of Digirad Corporation.
Forward-Looking Statements
Digirad cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. You can identify these statements by the fact that they do not relate strictly to historical or current facts and use words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” and other words and terms of similar meaning in connection with a discussion of future operating or financial performance or events. Examples of such statements include statements regarding the Company’s centers of influence expansion strategy and top and bottom line growth projections. The inclusion of these and other forward-looking statements should not be regarded as a representation by Digirad that any of its plans will be achieved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in Digirad’s business, market conditions, overall business prospects and operations; and other risks detailed in Digirad’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Form 8-K and other reports. Given these uncertainties, readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Digirad undertakes no obligation to revise or update this press release including the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
d.matsui@allencaron.com ir@digirad.com
CONTACT: Investors, Dan Matsui of Allen & Caron, +1-949-474-4300,
d.matsui@allencaron.com, for Digirad; or Mark Casner, CEO of Digirad,
+1-858-726-1600, ir@digirad.com
Web site: http://www.digirad.com/
